Using its patented BioBrace Implant technology, New Haven, Connecticut-based Biorez is working to improve the recovery of soft tissue. The BioBrace Implant is a cutting-edge bioinductive scaffold designed to strengthen soft tissue where it is weak and speed up healing. The FDA has approved the use of BioBrace in a variety of product sizes. The Company’s current credit facility is being used to pay for the transaction.
CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
Biorez is a New Haven, CT based medical device start-up focused on advancing the healing of soft tissues using its proprietary BioBrace Implant technology.
The forward-looking statements in this press release, as well as any previous disclosures, may be based on various assumptions and contingencies that are subject to risks and uncertainties. As a result, actual results, performance, or trends may differ materially from those projected in the forward-looking statements. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks posed to the Company’s business, financial condition, and results of operations by the COVID-19 global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability; the ability of CONMED to advance Biorez’s product lines following the Merger, including challenges and uncertainties inherent in product research and development, and the uncertain impact, outcome and cost of ongoing and future clinical trials and market studies; the potential effects of the Merger on relationships with employees, customers, other business partners or governmental entities; any assumptions underlying any of the foregoing; as well as risk factors discussed in the Company’s Annual Report on Form 10-K for the full year ended December 31, 2021 and other risks and uncertainties which may be detailed from time to time in reports filed by CONMED with the U.S. Securities and Exchange Commission.
CONMED’s shareholders and other investors are advised not to place undue reliance on any such forward-looking statements as they are not assurances of future performance and actual outcomes could differ considerably from those presently anticipated. All forward-looking statements are based on information that is currently available to CONMED, and unless as specifically required by law, CONMED disclaims any duty to update any such forward-looking statements to reflect new information, future developments, or other factors.
There can be no guarantee that management’s plans, views, or predictions as indicated in the forward-looking statements will materialise or turn out to be accurate, although the company believes that the forward-looking statements it has made have a reasonable basis.